Page 399 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 20 Melanoma 377

11. Todoroff RJ, Brodey RS: Oral and pharyngeal neoplasia in the dog: 35. Berrington AJ, Jimbow K, Haines DM: Immunohistochemical
a retrospective survey of 361 cases, J Am Vet Med Assoc 175:567– detection of melanoma-associated antigens on formalin-fixed,
571, 1979. paraffin-embedded canine tumors, Vet Pathol 31:455–461, 1994.
VetBooks.ir 12. Wallace J, Matthiesen DT, Patnaik AK: Hemimaxillectomy for the 36. Koenig A, Wojcieszyn J, Weeks BR, et al.: Expression of S100a,
vimentin, NSE, and melan A/MART-1 in seven canine melanoma
treatment of oral tumors in 69 dogs, Vet Surg 21:337–341, 1992.
13. Hahn KA, DeNicola DB, Richardson RC, et al.: Canine oral
malignant melanoma: prognostic utility of an alternative staging cells lines and twenty-nine retrospective cases of canine melanoma,
Vet Pathol 38:427–435, 2001.
system, J Small Anim Pract 35:251–256, 1994. 37. Sandusky GEJ, Carlton WW, Wightman KA: Immunohistochemi-
14. Dobson JM: Breed-predispositions to cancer in pedigree dog, Vet cal staining for S100 protein in the diagnosis of canine amelanotic
Sci 941275, 2013. melanoma, Vet Pathol 22:577–581, 1985.
15. Boerkamp KM, Teske E, Boon LR, et al.: Estimated incidence rate 38. Giudice C, Ceciliani F, Rondena M, et al.: Immunohistochemical
and distribution of tumours in 4,653 cases of archival submissions investigation of PNL2 reactivity of canine melanocytic neoplasms
derived from the Dutch golden retriever population, BMC Vet Res and comparison with Melan A, J Vet Diagn Invest 22:389–394,
10(34), 2014. 2010.
16. Ramos-Vara JA, Beissenherz ME, Miller MA, et al.: Retrospective 39. Ramos-Vara JA, Miller MA: Immunohistochemical identification
study of 338 canine oral melanomas with clinical, histologic, and of canine melanocytic neoplasms with antibodies to melanocytic
immunohistochemical review of 129 cases, Vet Pathol 37:597–608, antigen PNL2 and tyrosinase: comparison with Melan A, Vet Pathol
2000. 48:443–450, 2011.
17. MacEwen EG, Patnaik AK, Harvey HJ, et al.: Canine oral mela- 40. Grandi F, Rocha RM, Miot HA, et al.: Immunoexpression of
noma: comparison of surgery versus surgery plus Corynebacterium S100A4 in canine skin melanomas and correlation with histopath-
parvum, Cancer Invest 4:397–402, 1986. ological parameters, Vet Q 34:98–104, 2014.
18. Harvey HJ, Macewen EG, Braun D, et al.: Prognostic criteria for 41. Palmieri G, Capone M, Ascierto ML, et al.: Main roads to mela-
dogs with oral melanoma, J Am Vet Med Assoc 178:580–582, 1981. noma, J Transl Med 7:86, 2009.
19. Bradley RL, Macewen EG, Loar AS: Mandibular resection for 42. Bollag G, Hirth P, Tsai J, et al.: Clinical efficacy of a RAF inhibitor
removal of oral tumors in 30 dogs and 6 cats, J Am Vet Med Assoc needs broad target blockade in BRAF-mutant melanoma, Nature
184:460–463, 1984. 467:596–599, 2010.
20. Harvey HJ: Oral tumors, Vet Clin North Am Small Anim Pract 43. Shelly S, Chien MB, Yip B, et al.: Exon 15 BRAF mutations are
15:493–500, 1985. uncommon in canine oral malignant melanomas, Mamm Genome
21. Kosovsky JK, Matthiesen DT, Marretta SM, et al.: Results of par- 16:211–217, 2005.
tial mandibulectomy for the treatment of oral tumors in 142 dogs, 44. Fowles JS, Denton CL, Gustafson DL: Comparative analysis of
Vet Surg 20:397–401, 1991. MAPK and PI3K/AKT pathway activation and inhibition in
22. Schobert CS, Labelle P, Dubielzig RR: Feline conjunctival mela- human and canine melanoma, Vet Comp Oncol 13:288–304, 2015.
noma: histopathological characteristics and clinical outcomes, Vet 45. Roels S, Tilmant K, Ducatelle R: p53 expression and apoptosis in
Ophthalmol 13:43–46, 2010. melanomas of dogs and cats, Res Vet Sci 70:19–25, 2001.
23. Planellas M, Pastor J, Torres MD, et al.: Unusual presentation of a 46. Roels SL, Van Daele AJ, Van Marck EA, et al.: DNA ploidy and
metastatic uveal melanoma in a cat, Vet Ophthalmol 13:391–394, nuclear morphometric variables for the evaluation of melanocytic
2010. tumors in dogs and cats, Am J Vet Res 61:1074–1079, 2000.
24. Munday JS, French AF, Martin SJ: Cutaneous malignant mela- 47. Modiano JF, Ritt MG, Wojcieszyn J: The molecular basis of canine
noma in an 11-month-old Russian blue cat, NZ Vet J 59:143–146, melanoma: pathogenesis and trends in diagnosis and therapy, J Vet
2011. Intern Med 13:163–174, 1999.
25. Morges MA, Zaks K: Malignant melanoma in pleural effusion in a 48. Ritt MG, Mayor J, Wojcieszyn J, et al.: Sustained nuclear localiza-
14-year-old cat, J Fel Med Surg 13:532–535, 2011. tion of p21/WAF-1 upon growth arrest induced by contact inhibi-
26. Farrelly J, Denman DL, Hohenhaus AE, et al.: Hypofractionated tion, Cancer Lett 158:73–84, 2000.
radiation therapy of oral melanoma in five cats, Vet Radiol Ultra- 49. Han JI, Kim DY, Na KJ: Dysregulation of the Wnt/beta-catenin
sound 45:91–93, 2004. signaling pathway in canine cutaneous melanotic tumor, Vet Pathol
27. Grahn BH, Peiffer RL, Cullen CL, et al.: Classification of feline 47:285–291, 2010.
intraocular neoplasms based on morphology, histochemical 50. Stell AJ, Dobson JM, Scase TJ, et al.: Evaluation of variants of
staining, and immunohistochemical labeling, Vet Ophthalmol melanoma-associated antigen genes and mRNA transcripts in mel-
9:395–403, 2006. anomas of dogs, Am J Vet Res 70:1512–1520, 2009.
28. Patnaik AK, Mooney S: Feline melanoma: a comparative study of 51. Thamm DH, Huelsmeyer MK, Mitzey AM, et al.: RT-PCR-based
ocular, oral, and dermal neoplasms, Vet Pathol 25:105–112, 1988. tyrosine kinase display profiling of canine melanoma: IGF-1 recep-
29. Luna LD, Higginbotham ML, Henry CJ, et al.: Feline non-ocular tor as a potential therapeutic target, Melanoma Res 20:35–42, 2010.
melanoma: a retrospective study of 23 cases (1991-1999), J Fel Med 52. Kent MS, Collins CJ, Ye F: Activation of the AKT and mammalian
Surg 2:173–181, 2000. target of rapamycin pathways and the inhibitory effects of rapamy-
30. Bostock DE: Prognosis after surgical excision of canine melanomas, cin on those pathways in canine malignant melanoma cell lines,
Vet Pathol 16:32–40, 1979. Am J Vet Res 70:263–269, 2009.
31. Spangler WL, Kass PH: The histologic and epidemiologic bases 53. Taylor KH, Smith AN, Higginbotham M, et al.: Expression of
for prognostic considerations in canine melanocytic neoplasia, Vet vascular endothelial growth factor in canine oral malignant mela-
Pathol 43:136–149, 2006. noma, Vet Comp Oncol 5:208–218, 2007.
32. Smedley RC, Lamoureux J, Sledge DG, et al.: Immunohistochemi- 54. Murua EH, Gunther K, Richter A, et al.: Absence of ras-gene hot-
cal diagnosis of canine oral amelanotic melanocytic neoplasms, Vet spot mutations in canine fibrosarcomas and melanomas, Anticancer
Pathol 48:32–40, 2011. Res 24:3027–3028, 2004.
33. Choi C, Kusewitt DF: Comparison of tyrosinase-related protein-2, 55. Dincer Z, Jasani B, Haywood S, et al.: Metallothionein expression
S-100, and Melan A immunoreactivity in canine amelanotic mela- in canine and feline mammary and melanotic tumours, J Comp
nomas, Vet Pathol 40:713–718, 2003. Pathol 125:130–136, 2001.
34. Przezdziecki R, Czopowicz M, Sapierzynski R: Accuracy of routine 56. Stiles J, Bienzle D, Render JA, et al.: Use of nested polymerase
cytology and immunocytochemistry in preoperative diagnosis of chain reaction (PCR) for detection of retroviruses from formalin-
oral amelanotic melanomas in dogs, Vet Clin Pathol 44:597–604, fixed, paraffin-embedded uveal melanomas in cats, Vet Ophthalmol
2015. 2:113–116, 1999.